Serine/threonine kinase inhibitors
US9708290B2 · kind B2 · utility
3Cited by
6References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 12, 2016 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Jan 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.